Steve Schonfeld’s Moderna MRNA Stock Holding History

Steve Schonfeld’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-150,000	Closed	-$6.24M	–	2389
2024 Q4	$6.24M	Buy	+150,000	New	+$7.17M	0.04%	429
2023 Q1	–	Sell	-100,000	Closed	-$152K	–	2430
2022 Q4	$152K	Buy	+100,000	New	+$16.4M	﹤0.01%	2077

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Steve Schonfeld's MRNA Position: Q2 2026 in Review

Steve Schonfeld sold out of Moderna (MRNA) in Q2 2026, closing a stake of 15,691 shares — an estimated $797K sold.

Steve Schonfeld first reported a position in MRNA in Q1 2020 and held it in 19 quarters. The position peaked at $16.5M in Q2 2024. 775 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Steve Schonfeld reported no remaining Moderna position as of Q2 2026 after selling out during the quarter.
Steve Schonfeld sold 15,691 Moderna shares in Q2 2026, an estimated $797K.
Steve Schonfeld first reported a position in Moderna in Q1 2020 and held it in 19 quarters.
Steve Schonfeld's Moderna position peaked at $16.5M in Q2 2024.
775 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.